Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Port Royal, SC
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Port Royal, SC
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Nashville, TN
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
DeSoto, TX
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
DeSoto, TX
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Richmond, VA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Bellevue, WA
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Bellevue, WA
Click here to add this to my saved trials
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated:  7/8/2015
TransitionTIL Investigational Site
mi
from
Calgary,
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status: Enrolling
Updated: 7/8/2015
TransitionTIL Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months
Status: Enrolling
Updated:  7/9/2015
University of Chicago
mi
from
Chicago, IL
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months
Status: Enrolling
Updated: 7/9/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Prospective Analysis of the Use of TEG in Stroke Patients
Prospective Analysis of the Use of Thromboelastography in Stroke Patients
Status: Enrolling
Updated:  7/9/2015
University of Texas Medical School in Houston
mi
from
Houston, TX
Prospective Analysis of the Use of TEG in Stroke Patients
Prospective Analysis of the Use of Thromboelastography in Stroke Patients
Status: Enrolling
Updated: 7/9/2015
University of Texas Medical School in Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated:  7/10/2015
Clinical Research Facility
mi
from
Mobile, AL
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated: 7/10/2015
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated:  7/10/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated: 7/10/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated:  7/10/2015
Clinical Research Facility
mi
from
Little Rock, AR
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated: 7/10/2015
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated:  7/10/2015
Clinical Research Facility
mi
from
Fairfield, CT
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated: 7/10/2015
Clinical Research Facility
mi
from
Fairfield, CT
Click here to add this to my saved trials
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated:  7/10/2015
Clinical Research Facility
mi
from
Bethesda, MD
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated: 7/10/2015
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated:  7/10/2015
Clinical Research Facility
mi
from
Dallas, TX
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy
Status: Enrolling
Updated: 7/10/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Sleep and Delirium in the Intensive Care Unit (ICU)
Sleep Disruption and ICU Delirium: Delirium Assessment and Monitoring Combined With the Evaluation of Sleep Using the Sedline Brain Function Monitor.
Status: Enrolling
Updated:  7/13/2015
University of California at San Francisco
mi
from
San Francisco, CA
Study of Sleep and Delirium in the Intensive Care Unit (ICU)
Sleep Disruption and ICU Delirium: Delirium Assessment and Monitoring Combined With the Evaluation of Sleep Using the Sedline Brain Function Monitor.
Status: Enrolling
Updated: 7/13/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO 2)
Status: Enrolling
Updated:  7/13/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO 2)
Status: Enrolling
Updated: 7/13/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy
Diffusion Tensor Imaging of the Brain and Cervical Spine: Evaluation of Reproducibility in Normal Subjects and Diagnostic Utility in Patients With Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  7/14/2015
Center for Systems Imaging (CSI), Emory University
mi
from
Atlanta, GA
DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy
Diffusion Tensor Imaging of the Brain and Cervical Spine: Evaluation of Reproducibility in Normal Subjects and Diagnostic Utility in Patients With Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 7/14/2015
Center for Systems Imaging (CSI), Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Therapeutic Plasma Exchange in MG
Exploratory Study Of Immunological Profiles In Myasthenia Gravis Subjects That Receive Therapeutic Plasma Exchange
Status: Enrolling
Updated:  7/15/2015
UNC Chapel Hill
mi
from
CHapel Hill, NC
Therapeutic Plasma Exchange in MG
Exploratory Study Of Immunological Profiles In Myasthenia Gravis Subjects That Receive Therapeutic Plasma Exchange
Status: Enrolling
Updated: 7/15/2015
UNC Chapel Hill
mi
from
CHapel Hill, NC
Click here to add this to my saved trials
Therapeutic Plasma Exchange in MG
Exploratory Study Of Immunological Profiles In Myasthenia Gravis Subjects That Receive Therapeutic Plasma Exchange
Status: Enrolling
Updated:  7/15/2015
Duke University Hospital
mi
from
Durham, NC
Therapeutic Plasma Exchange in MG
Exploratory Study Of Immunological Profiles In Myasthenia Gravis Subjects That Receive Therapeutic Plasma Exchange
Status: Enrolling
Updated: 7/15/2015
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Tucson Clinical Site 133
mi
from
Tucson, AZ
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Tucson Clinical Site 133
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Aurora Clinical Site 132
mi
from
Aurora, CO
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Aurora Clinical Site 132
mi
from
Aurora, CO
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Fort Collins Clinical Site 123
mi
from
Fort Collins, CO
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Fort Collins Clinical Site 123
mi
from
Fort Collins, CO
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Fairfield Clincial Site 110
mi
from
Fairfield, CT
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Fairfield Clincial Site 110
mi
from
Fairfield, CT
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Ormond Beach Clinical Site 129
mi
from
Ormond Beach, FL
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Ormond Beach Clinical Site 129
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Sarasota Clinical Site 116
mi
from
Sarasota, FL
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Sarasota Clinical Site 116
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Northbrook Clinical Site 135
mi
from
Northbrook, IL
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Northbrook Clinical Site 135
mi
from
Northbrook, IL
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Fort Wayne Clinical Site 111
mi
from
Fort Wayne, IN
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Fort Wayne Clinical Site 111
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Indianapolis Clinical Site 121
mi
from
Indianapolis, IN
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Indianapolis Clinical Site 121
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Detroit Clinical Site 104
mi
from
Detroit, MI
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Detroit Clinical Site 104
mi
from
Detroit, MI
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Farmington Hills Clinical Site 126
mi
from
Farmington Hills, MI
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Farmington Hills Clinical Site 126
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Lebanon Clinical Site 115
mi
from
Lebanon, NH
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Lebanon Clinical Site 115
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Albuquerque Clinical Site 106
mi
from
Albuquerque, NM
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Albuquerque Clinical Site 106
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Rochester Clinical Site
mi
from
Rochester, NY
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Rochester Clinical Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Charlotte Clinical Site 125
mi
from
Charlotte, NC
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Charlotte Clinical Site 125
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Raleigh Clinical Site 103
mi
from
Raleigh, NC
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Raleigh Clinical Site 103
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Akron Clinical Site 112
mi
from
Akron, OH
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Akron Clinical Site 112
mi
from
Akron, OH
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Knoxville Clinical Site 134
mi
from
Knoxville, TN
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Knoxville Clinical Site 134
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Round Rock Clinical Site 107
mi
from
Round Rock, TX
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Round Rock Clinical Site 107
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Brugge Clinical Site 203
mi
from
Brugge,
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Brugge Clinical Site 203
mi
from
Brugge,
Click here to add this to my saved trials
Smart Phone Application for Postconcussion Symptom Reduction
Smart Phone Application for Postconcussion Symptoms Reduction
Status: Enrolling
Updated:  7/15/2015
James A. Haley Veterans Hospital
mi
from
Tampa, FL
Smart Phone Application for Postconcussion Symptom Reduction
Smart Phone Application for Postconcussion Symptoms Reduction
Status: Enrolling
Updated: 7/15/2015
James A. Haley Veterans Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation
Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation
Status: Enrolling
Updated:  7/17/2015
University of Florida
mi
from
Gainesville, FL
Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation
Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation
Status: Enrolling
Updated: 7/17/2015
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Status: Enrolling
Updated:  7/17/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
Status: Enrolling
Updated: 7/17/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Transcranial Doppler Ultrasound Monitoring During Flow-Diverter Embolization
A Prospective Study of the Treatment of Intracranial Aneurysms Using Pipeline Flow-Diverter Embolization in Conjunction With Transcranial Dopplers (TCD)
Status: Enrolling
Updated:  7/17/2015
University of Florida
mi
from
Gainesville, FL
Transcranial Doppler Ultrasound Monitoring During Flow-Diverter Embolization
A Prospective Study of the Treatment of Intracranial Aneurysms Using Pipeline Flow-Diverter Embolization in Conjunction With Transcranial Dopplers (TCD)
Status: Enrolling
Updated: 7/17/2015
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Child and Infant Learning Project
Neurobehavioral Correlates of Craniosynostosis
Status: Enrolling
Updated:  7/19/2015
Children's Health Care of Atlanta
mi
from
Atlanta, GA
Child and Infant Learning Project
Neurobehavioral Correlates of Craniosynostosis
Status: Enrolling
Updated: 7/19/2015
Children's Health Care of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Child and Infant Learning Project
Neurobehavioral Correlates of Craniosynostosis
Status: Enrolling
Updated:  7/19/2015
Northwestern University, Cleft Lip and Palate Institute
mi
from
Westchester, IL
Child and Infant Learning Project
Neurobehavioral Correlates of Craniosynostosis
Status: Enrolling
Updated: 7/19/2015
Northwestern University, Cleft Lip and Palate Institute
mi
from
Westchester, IL
Click here to add this to my saved trials
Child and Infant Learning Project
Neurobehavioral Correlates of Craniosynostosis
Status: Enrolling
Updated:  7/19/2015
St. Louis Children's Hospital, Washington University
mi
from
St. Louis, MO
Child and Infant Learning Project
Neurobehavioral Correlates of Craniosynostosis
Status: Enrolling
Updated: 7/19/2015
St. Louis Children's Hospital, Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Child and Infant Learning Project
Neurobehavioral Correlates of Craniosynostosis
Status: Enrolling
Updated:  7/19/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Child and Infant Learning Project
Neurobehavioral Correlates of Craniosynostosis
Status: Enrolling
Updated: 7/19/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases
Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases
Status: Enrolling
Updated:  7/20/2015
Duke University Health System
mi
from
Durham, NC
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases
Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases
Status: Enrolling
Updated: 7/20/2015
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)
BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)
Status: Enrolling
Updated:  7/20/2015
Alabama Neurological Institute
mi
from
Birmingham, AL
BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)
BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)
Status: Enrolling
Updated: 7/20/2015
Alabama Neurological Institute
mi
from
Birmingham, AL
Click here to add this to my saved trials